SlideShare a Scribd company logo
1 of 14
Download to read offline
Realizing Possibilities, Together
Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
CROSS-BORDER LIFESCIENCES DEALS (2013-2015):
A Perspective
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
Dinesh Jain| Michael Rosen
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 2
Table of Contents
Overall Pharma Market Trends
M&A
Joint Ventures/Co-Development
Licensing
Aagami Profile
CROSS BORDER LIFESCIENCES DEALS - US & INDIA (2013-2015)
Note : These are some of the deals which Aagami Market Research Team have sourced
from Publicly available data and hence not exhaustive
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 3
• Indian Pharma Market = ~ $22 B; projected to
grow to $55 B by 2020 (McKinsey)
• India pharma exports $15.2 B in pharmaceutical
products ($4.2B to US)
• 584 FDA –approved pharma manufacturing
facilities
• >3,000 pharma companies
• Bi-national M&A (2013-2015)*
 U.S. pharma spent more than $2.7 B to acquire Indian
pharma
 Indian pharma spent $180 M to acquire U.S. biotech
and >$180 M in FDI
* Counting only deal amounts which were publicly disclosed
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 4
Indian Co. US Co.
Deal Size - M Year Remarks
Aurobindo Natrol Inc. $132.5 2014 Nutraceuticals platform for US & ROW
Piramal
Coldstream
Laboratories
$30.65 2015 Injectable market segment
SRF
Dupont $ 20 .0 2015 Pharma propellant business
Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business
Kemwell
Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for
customers
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 5
US Co. Indian Co. Deal Size - M Year Remarks
Mylan Agila $1,600 2013 Become top-three global player in injectables
Mylan Famy Care $800 2015 Global women's health care
Hospira
Orchid
Pharma
$200 2014 API supplier for key antibiotics and future API development.
Carlyle
Group
Bharat
Serum $83 2014 25-30% stake from existing investors.
Amneal
Pharma
Epsilon
Pharma
$16 2014
Expand footprint in India. Includes 200,000 + sf. US FDA
certified manufacturing facility.
Quantum
solutions
Parexel N/A 2015
Create greater scale in service area, and provide
comprehensive and efficient solution to global clients.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 6
Indian Co. US Co. Year Remarks
Ami Organics Photolitec 2015
Clinical trials to determine cancer treatments safety and
and efficacy.
Emami
Hevert-
Arzneimittel
2014
Launched products via 400 homoeopathy medicine retail
outlets across diverse distribution channels via Emami.
Agila Biotech Pfenex Inc 2013
Develop, manufacture and commercialize initial pipeline of
6 biosimilar products. AB = 51% equity stakeholder
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 7
Indian Co. US Co. Year Remarks
Ipca
Labs
Oncobiologics 2014
Development, manufacture and commercialization of biosimilar monoclonal
antibodies.
Cipla BioQuiddity 2014
Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications
for post-surgical pain management.
GVK Bio Endo Pharma 2013
Novel small molecules. GVK BIO will use discovery expertise and Endo will
develop/commercialize product.
Advinus
Moffitt Cancer
Centre
2013 New oncology therapies.
GVK Bio
Onconova
Therapeutics
2013
US JV to move Onconova oncology assets from early discovery to clinical
development stage.
Cadila Novavax 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 8
Indian Co. US Co. Deal Size - M Year Remarks
Lupin US Market $177.5 2014
2 new US R&D Centres on inhalation and complex formulations
research.
Glenmark US Market $100 2014 Greenfield facility for US market.
Cipla Chase Pharma $6.0 2014
Alzheimer’s drug development. Part of $21 M investment
through syndicate.
Strides
Arcolabs
Oncobiologics N/A 2014 Strategic stake.
Indian Co. US Co. Deal Size - M Year Remarks
Laurus Lab Warburg Pincus $92 2014 Create durable businesses of scale with sustainable value.
Ashland
Investment in
India
$ 10 2014 2 centres of excellence — new pharma in Hyderabad and
existing personal care in Mumbai
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 9
Indian Co. US Co. Year Remarks
Sun Pharma Merck 2014 Worldwide rights to tildrakizumab. $ 280 M Deal
MedGenome Natera 2015 Exclusive license to develop Natera's Panorama.
Strides
Arcolabs
Gilead 2015 Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license
extends to 112 countries
Natco India Gilead 2015 Generic versions of chronic hepatitis C medicines.
Ranbaxy Epirus 2014 Infliximab (arthritis) with annual sales of $6 billion..
Biocon Cytosorbents
Corporation
2014 Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications
for India and select emerging countries.
Indian Co. US Co. Year Remarks
Caplin Point Fresenius
Kabi
2015 Parenteral products; Fresenius Kabi will hold ANDAs and commercialise in USA.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
10
Aagami, Inc.
Life Sciences consulting firm based in
Chicago suburbs offers:
For Global Biotech, Pharmaceutical , Medical Devices and Consumer
Health products companies.
Strategic Consulting Services
Technology Licensing Services
Business & Market Research Services
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
11
Strategic Consulting Services
 In-Licensing/Out-Licensing
 Co-Development & Partnerships
 Investments to/from US, India, Asia, Latin America
 Mergers & Acquisitions
 Finding the Right Partners
 JV and/or Distributors
 CRO/CRAMS providers
 Contract Sales/Marketing
 Contract Manufacturing
12
Aagami Clients
International
Phosphagenics Australia
PeptiSyntha Belgium
DelMar Pharma Canada
Affitech Denmark
Pieris Germany
Merus Holland
Venus Remedies India
Opsona Ireland
Toppan Japan
Otago University New Zealand
Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years.
United States
Advangene IL
Loyola Univ. Chicago IL
Dow Chemicals MI
ScyFIX MN
OncBioMune LA
Penwest Corp. NY
DesignMedix OR
PLx TX
CreAgri CA
New Heaven Pharma CT
13
Aagami Connectivity in India
We are connected at CXO Level of TOP 100 Lifesciences companies
in India including:
Biocon Intas Sun Pharma
Cadila Lupin Themis
Cipla MicroLabs Torrent Pharma
Dr Reddys Piramal USV
Glenmark Reliance Wockhardt
Hetero Drugs Strides Zydus
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
USA (Head Office)
Aagami, Inc.
2135 City Gate Lane Suite 300
Naperville, IL 60653
P: +1-630-364-1837
INDIA
Aagami
741, Nelson Square
Nagpur – 440013
P: +91-712-258-6678
Dinesh Jain
Email: dinesh@aagami.com
M: +1 630-853-3520
Godwyn Francis
Email: godwyn@aagami.com
M: +91-787-501-6957
www.aagami.com
14
Realizing Possibilities, Together

More Related Content

What's hot

IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
Katalyst Wealth
 
VENTURE CAPITAL
VENTURE CAPITALVENTURE CAPITAL
VENTURE CAPITAL
crmasfabe
 
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
Aagami, Inc.
 
Complex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and ChallengesComplex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and Challenges
Sanjay Chaturvedi
 

What's hot (20)

pankaj patel- cadila healthcare
pankaj patel- cadila healthcarepankaj patel- cadila healthcare
pankaj patel- cadila healthcare
 
Mp advisors sa deals 2013.pdf
Mp advisors sa deals 2013.pdfMp advisors sa deals 2013.pdf
Mp advisors sa deals 2013.pdf
 
Aagami Consutling
Aagami ConsutlingAagami Consutling
Aagami Consutling
 
Cipla Presentation
Cipla PresentationCipla Presentation
Cipla Presentation
 
Mis project
Mis projectMis project
Mis project
 
Sun pharma
Sun pharmaSun pharma
Sun pharma
 
Cipla presentation
Cipla presentationCipla presentation
Cipla presentation
 
IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
IPCA Laboratories ltd (NSE Code IPCALAB) - Nov'12 Katalyst Wealth Alpha recom...
 
Mp Advisors June12
Mp Advisors June12Mp Advisors June12
Mp Advisors June12
 
VENTURE CAPITAL
VENTURE CAPITALVENTURE CAPITAL
VENTURE CAPITAL
 
DR REDDYS LABS PPT
DR REDDYS LABS PPTDR REDDYS LABS PPT
DR REDDYS LABS PPT
 
Research Report on Cipla Limited
Research Report on Cipla Limited Research Report on Cipla Limited
Research Report on Cipla Limited
 
Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.
 
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
Aagami Case Study - Technology Out-licensing of Transdermal Drug Delivery Tec...
 
Sun pharma Presentation
Sun pharma PresentationSun pharma Presentation
Sun pharma Presentation
 
Fundamental Analysis of Aurobindo Pharma Stock
Fundamental Analysis of Aurobindo Pharma StockFundamental Analysis of Aurobindo Pharma Stock
Fundamental Analysis of Aurobindo Pharma Stock
 
Complex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and ChallengesComplex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and Challenges
 
Dr. Reddy's Laboratories
Dr. Reddy's LaboratoriesDr. Reddy's Laboratories
Dr. Reddy's Laboratories
 
Dr. Reddy's Lab - Business Model
Dr. Reddy's Lab - Business ModelDr. Reddy's Lab - Business Model
Dr. Reddy's Lab - Business Model
 
Dr.reddy labs financial analysis
Dr.reddy labs financial analysisDr.reddy labs financial analysis
Dr.reddy labs financial analysis
 

Similar to Presentation made by Aagami at Lifesciences Summit at CGI - 18 May

Saral Gyan Value Pick - Jan 2013
Saral Gyan Value Pick - Jan 2013Saral Gyan Value Pick - Jan 2013
Saral Gyan Value Pick - Jan 2013
SaralGyanTeam
 
Aagami Inc. Company Presentation
Aagami Inc. Company PresentationAagami Inc. Company Presentation
Aagami Inc. Company Presentation
Godwyn Francis
 
Overseas Acquisitions in lifesciences by Indian Companies
Overseas Acquisitions in lifesciences by Indian CompaniesOverseas Acquisitions in lifesciences by Indian Companies
Overseas Acquisitions in lifesciences by Indian Companies
Godwyn Francis
 
Summer Internship Report
Summer Internship ReportSummer Internship Report
Summer Internship Report
Pramod Patidar
 
Indian pharma outlook
Indian pharma outlookIndian pharma outlook
Indian pharma outlook
jatin125
 

Similar to Presentation made by Aagami at Lifesciences Summit at CGI - 18 May (20)

M&A in Pharma
M&A in PharmaM&A in Pharma
M&A in Pharma
 
Saral Gyan Value Pick - Jan 2013
Saral Gyan Value Pick - Jan 2013Saral Gyan Value Pick - Jan 2013
Saral Gyan Value Pick - Jan 2013
 
Working capital management of Jubilant Life Sciences (2)
Working capital management of Jubilant Life Sciences (2)Working capital management of Jubilant Life Sciences (2)
Working capital management of Jubilant Life Sciences (2)
 
Avanafil Api Manufacturer in India | Pharmaadda
Avanafil Api Manufacturer in India | PharmaaddaAvanafil Api Manufacturer in India | Pharmaadda
Avanafil Api Manufacturer in India | Pharmaadda
 
Aagami Inc. Company Presentation
Aagami Inc. Company PresentationAagami Inc. Company Presentation
Aagami Inc. Company Presentation
 
Overseas Acquisitions in lifesciences by Indian Companies
Overseas Acquisitions in lifesciences by Indian CompaniesOverseas Acquisitions in lifesciences by Indian Companies
Overseas Acquisitions in lifesciences by Indian Companies
 
Aagami Corporate Presentation April 2022
Aagami Corporate Presentation April 2022Aagami Corporate Presentation April 2022
Aagami Corporate Presentation April 2022
 
Summer Internship Report
Summer Internship ReportSummer Internship Report
Summer Internship Report
 
Karomi Technology Corporate Capability Showcase
Karomi Technology Corporate Capability ShowcaseKaromi Technology Corporate Capability Showcase
Karomi Technology Corporate Capability Showcase
 
Business development of sunpharma presentation 3.pptx
Business development of sunpharma presentation 3.pptxBusiness development of sunpharma presentation 3.pptx
Business development of sunpharma presentation 3.pptx
 
Indian pharma outlook
Indian pharma outlookIndian pharma outlook
Indian pharma outlook
 
Veterinary services
Veterinary servicesVeterinary services
Veterinary services
 
Aagami Corporate Presentation
Aagami Corporate PresentationAagami Corporate Presentation
Aagami Corporate Presentation
 
Rbsa india deals snapshot march 2016
Rbsa india deals snapshot march 2016Rbsa india deals snapshot march 2016
Rbsa india deals snapshot march 2016
 
Granules india
Granules indiaGranules india
Granules india
 
Finance report on alembic pharmaceuticals
Finance report on alembic pharmaceuticalsFinance report on alembic pharmaceuticals
Finance report on alembic pharmaceuticals
 
Director of Sales - Consumer Heath Care - Strides Shasun INC. USA
Director of Sales - Consumer Heath Care - Strides Shasun INC. USADirector of Sales - Consumer Heath Care - Strides Shasun INC. USA
Director of Sales - Consumer Heath Care - Strides Shasun INC. USA
 
Top pharma syrup manufacturer in india ppt
Top pharma syrup manufacturer in india pptTop pharma syrup manufacturer in india ppt
Top pharma syrup manufacturer in india ppt
 
Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..
 
Aarti Drugs Ltd (NSE Code - AARTIDRUGS) - Feb'14 Katalyst Wealth Alpha Recomm...
Aarti Drugs Ltd (NSE Code - AARTIDRUGS) - Feb'14 Katalyst Wealth Alpha Recomm...Aarti Drugs Ltd (NSE Code - AARTIDRUGS) - Feb'14 Katalyst Wealth Alpha Recomm...
Aarti Drugs Ltd (NSE Code - AARTIDRUGS) - Feb'14 Katalyst Wealth Alpha Recomm...
 

More from Aagami, Inc.

Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
Aagami, Inc.
 
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
Aagami, Inc.
 
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
Aagami, Inc.
 
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
Aagami, Inc.
 
Aagami Case Study - Reducing cost of creation and management of MSDS
Aagami Case Study - Reducing cost of creation and management of MSDSAagami Case Study - Reducing cost of creation and management of MSDS
Aagami Case Study - Reducing cost of creation and management of MSDS
Aagami, Inc.
 
Infrastructure Requirements for e2Commerce
Infrastructure Requirements for e2CommerceInfrastructure Requirements for e2Commerce
Infrastructure Requirements for e2Commerce
Aagami, Inc.
 

More from Aagami, Inc. (16)

Aagami Corporate Presentation March 2024
Aagami Corporate Presentation March 2024Aagami Corporate Presentation March 2024
Aagami Corporate Presentation March 2024
 
Aagami Inc. Corporate Presentation JPM 2024
Aagami Inc. Corporate Presentation JPM 2024Aagami Inc. Corporate Presentation JPM 2024
Aagami Inc. Corporate Presentation JPM 2024
 
Aagami Corporate Presentation 2023
Aagami Corporate Presentation 2023Aagami Corporate Presentation 2023
Aagami Corporate Presentation 2023
 
Aagami Market Intelligence Presentation
Aagami Market Intelligence PresentationAagami Market Intelligence Presentation
Aagami Market Intelligence Presentation
 
Aagami Technology Licensing Presentation
Aagami Technology Licensing PresentationAagami Technology Licensing Presentation
Aagami Technology Licensing Presentation
 
Consulate General of India - Chicago - Lifescience summit Agenda
Consulate General of India - Chicago - Lifescience summit AgendaConsulate General of India - Chicago - Lifescience summit Agenda
Consulate General of India - Chicago - Lifescience summit Agenda
 
Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD an...
 
Study of Market Potential and Prospective Partners in India for hand-held qPC...
Study of Market Potential and Prospective Partners in India for hand-held qPC...Study of Market Potential and Prospective Partners in India for hand-held qPC...
Study of Market Potential and Prospective Partners in India for hand-held qPC...
 
Aagami Select List of Clients
Aagami Select List of ClientsAagami Select List of Clients
Aagami Select List of Clients
 
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
Aagami Case Study - Assessment of the Market Need of a POC Diagnostic Device ...
 
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
Aagami Case Study - Competitive Landscape Analysis in India to finalize Prici...
 
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
Aagami Case Study - Assessment of Global Net Present Value (NPV) of a revolut...
 
Aagami Case Study - Reducing cost of creation and management of MSDS
Aagami Case Study - Reducing cost of creation and management of MSDSAagami Case Study - Reducing cost of creation and management of MSDS
Aagami Case Study - Reducing cost of creation and management of MSDS
 
Aagami Performance Scorecard
Aagami Performance ScorecardAagami Performance Scorecard
Aagami Performance Scorecard
 
Amazing Facts and Figures - A compilation by Aagami
Amazing Facts and Figures - A compilation by AagamiAmazing Facts and Figures - A compilation by Aagami
Amazing Facts and Figures - A compilation by Aagami
 
Infrastructure Requirements for e2Commerce
Infrastructure Requirements for e2CommerceInfrastructure Requirements for e2Commerce
Infrastructure Requirements for e2Commerce
 

Recently uploaded

Advancing Impact Measurement | Public Good App House
Advancing Impact Measurement | Public Good App HouseAdvancing Impact Measurement | Public Good App House
Advancing Impact Measurement | Public Good App House
TechSoup
 
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
enbam
 
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
enbam
 
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
enbam
 
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
enbam
 
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
aveka1
 
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
enbam
 

Recently uploaded (20)

Minority economic forum Executive Summary
Minority economic forum Executive SummaryMinority economic forum Executive Summary
Minority economic forum Executive Summary
 
A House is not a Home Yale Historical Reivew
A House is not a Home Yale Historical ReivewA House is not a Home Yale Historical Reivew
A House is not a Home Yale Historical Reivew
 
Advancing Impact Measurement | Public Good App House
Advancing Impact Measurement | Public Good App HouseAdvancing Impact Measurement | Public Good App House
Advancing Impact Measurement | Public Good App House
 
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
一比一原版(Adelaide毕业证)阿德莱德大学毕业证成绩单
 
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
一比一原版(GU毕业证)格里菲斯大学毕业证成绩单
 
CrossWalksInspirations for Brockville***
CrossWalksInspirations for Brockville***CrossWalksInspirations for Brockville***
CrossWalksInspirations for Brockville***
 
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
一比一原版(ANU毕业证)澳大利亚国立大学毕业证成绩单
 
Proposed Facility Types: Chesapeake Trails and Connectivity Plan
Proposed Facility Types: Chesapeake Trails and Connectivity PlanProposed Facility Types: Chesapeake Trails and Connectivity Plan
Proposed Facility Types: Chesapeake Trails and Connectivity Plan
 
07/03/2024 Publiekdomeindag - namiddag
07/03/2024 Publiekdomeindag - namiddag07/03/2024 Publiekdomeindag - namiddag
07/03/2024 Publiekdomeindag - namiddag
 
“Be part of the Plan” International Day For Biological Diversity 2024.
“Be part of the Plan” International Day For Biological Diversity 2024.“Be part of the Plan” International Day For Biological Diversity 2024.
“Be part of the Plan” International Day For Biological Diversity 2024.
 
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
一比一原版(MQU毕业证)麦考瑞大学毕业证成绩单
 
Writing Sample-Title: Pioneering Urban Transformation: The Collective Power o...
Writing Sample-Title: Pioneering Urban Transformation: The Collective Power o...Writing Sample-Title: Pioneering Urban Transformation: The Collective Power o...
Writing Sample-Title: Pioneering Urban Transformation: The Collective Power o...
 
Medieval Iraq Demographic Factors Yale Historical Review
Medieval Iraq Demographic Factors Yale Historical ReviewMedieval Iraq Demographic Factors Yale Historical Review
Medieval Iraq Demographic Factors Yale Historical Review
 
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
一比一原版(SUT毕业证)斯威本科技大学毕业证成绩单
 
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
一比一原版(UQ毕业证)昆士兰大学毕业证成绩单
 
Creating an Effective Veteran Policy in Ukraine
Creating an Effective Veteran Policy in UkraineCreating an Effective Veteran Policy in Ukraine
Creating an Effective Veteran Policy in Ukraine
 
How to Save a Place: How to Fund Your Preservation Project
How to Save a Place: How to Fund Your Preservation ProjectHow to Save a Place: How to Fund Your Preservation Project
How to Save a Place: How to Fund Your Preservation Project
 
Effective governance in the modern charity
Effective governance in the modern charityEffective governance in the modern charity
Effective governance in the modern charity
 
Ghana High Commission on list of diplomats including US & China who owe £143m...
Ghana High Commission on list of diplomats including US & China who owe £143m...Ghana High Commission on list of diplomats including US & China who owe £143m...
Ghana High Commission on list of diplomats including US & China who owe £143m...
 
#Bepartoftheplan on International Day For Biological Diversity 2024
#Bepartoftheplan on International Day For Biological Diversity 2024#Bepartoftheplan on International Day For Biological Diversity 2024
#Bepartoftheplan on International Day For Biological Diversity 2024
 

Presentation made by Aagami at Lifesciences Summit at CGI - 18 May

  • 1. Realizing Possibilities, Together Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com CROSS-BORDER LIFESCIENCES DEALS (2013-2015): A Perspective © Aagami, Inc. 2015 | All rights reserved | www.aagami.com Dinesh Jain| Michael Rosen
  • 2. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 2 Table of Contents Overall Pharma Market Trends M&A Joint Ventures/Co-Development Licensing Aagami Profile CROSS BORDER LIFESCIENCES DEALS - US & INDIA (2013-2015) Note : These are some of the deals which Aagami Market Research Team have sourced from Publicly available data and hence not exhaustive
  • 3. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 3 • Indian Pharma Market = ~ $22 B; projected to grow to $55 B by 2020 (McKinsey) • India pharma exports $15.2 B in pharmaceutical products ($4.2B to US) • 584 FDA –approved pharma manufacturing facilities • >3,000 pharma companies • Bi-national M&A (2013-2015)*  U.S. pharma spent more than $2.7 B to acquire Indian pharma  Indian pharma spent $180 M to acquire U.S. biotech and >$180 M in FDI * Counting only deal amounts which were publicly disclosed
  • 4. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 4 Indian Co. US Co. Deal Size - M Year Remarks Aurobindo Natrol Inc. $132.5 2014 Nutraceuticals platform for US & ROW Piramal Coldstream Laboratories $30.65 2015 Injectable market segment SRF Dupont $ 20 .0 2015 Pharma propellant business Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business Kemwell Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for customers
  • 5. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 5 US Co. Indian Co. Deal Size - M Year Remarks Mylan Agila $1,600 2013 Become top-three global player in injectables Mylan Famy Care $800 2015 Global women's health care Hospira Orchid Pharma $200 2014 API supplier for key antibiotics and future API development. Carlyle Group Bharat Serum $83 2014 25-30% stake from existing investors. Amneal Pharma Epsilon Pharma $16 2014 Expand footprint in India. Includes 200,000 + sf. US FDA certified manufacturing facility. Quantum solutions Parexel N/A 2015 Create greater scale in service area, and provide comprehensive and efficient solution to global clients.
  • 6. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 6 Indian Co. US Co. Year Remarks Ami Organics Photolitec 2015 Clinical trials to determine cancer treatments safety and and efficacy. Emami Hevert- Arzneimittel 2014 Launched products via 400 homoeopathy medicine retail outlets across diverse distribution channels via Emami. Agila Biotech Pfenex Inc 2013 Develop, manufacture and commercialize initial pipeline of 6 biosimilar products. AB = 51% equity stakeholder
  • 7. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 7 Indian Co. US Co. Year Remarks Ipca Labs Oncobiologics 2014 Development, manufacture and commercialization of biosimilar monoclonal antibodies. Cipla BioQuiddity 2014 Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications for post-surgical pain management. GVK Bio Endo Pharma 2013 Novel small molecules. GVK BIO will use discovery expertise and Endo will develop/commercialize product. Advinus Moffitt Cancer Centre 2013 New oncology therapies. GVK Bio Onconova Therapeutics 2013 US JV to move Onconova oncology assets from early discovery to clinical development stage. Cadila Novavax 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.
  • 8. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 8 Indian Co. US Co. Deal Size - M Year Remarks Lupin US Market $177.5 2014 2 new US R&D Centres on inhalation and complex formulations research. Glenmark US Market $100 2014 Greenfield facility for US market. Cipla Chase Pharma $6.0 2014 Alzheimer’s drug development. Part of $21 M investment through syndicate. Strides Arcolabs Oncobiologics N/A 2014 Strategic stake. Indian Co. US Co. Deal Size - M Year Remarks Laurus Lab Warburg Pincus $92 2014 Create durable businesses of scale with sustainable value. Ashland Investment in India $ 10 2014 2 centres of excellence — new pharma in Hyderabad and existing personal care in Mumbai
  • 9. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 9 Indian Co. US Co. Year Remarks Sun Pharma Merck 2014 Worldwide rights to tildrakizumab. $ 280 M Deal MedGenome Natera 2015 Exclusive license to develop Natera's Panorama. Strides Arcolabs Gilead 2015 Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license extends to 112 countries Natco India Gilead 2015 Generic versions of chronic hepatitis C medicines. Ranbaxy Epirus 2014 Infliximab (arthritis) with annual sales of $6 billion.. Biocon Cytosorbents Corporation 2014 Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications for India and select emerging countries. Indian Co. US Co. Year Remarks Caplin Point Fresenius Kabi 2015 Parenteral products; Fresenius Kabi will hold ANDAs and commercialise in USA.
  • 10. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 10 Aagami, Inc. Life Sciences consulting firm based in Chicago suburbs offers: For Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies. Strategic Consulting Services Technology Licensing Services Business & Market Research Services
  • 11. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 11 Strategic Consulting Services  In-Licensing/Out-Licensing  Co-Development & Partnerships  Investments to/from US, India, Asia, Latin America  Mergers & Acquisitions  Finding the Right Partners  JV and/or Distributors  CRO/CRAMS providers  Contract Sales/Marketing  Contract Manufacturing
  • 12. 12 Aagami Clients International Phosphagenics Australia PeptiSyntha Belgium DelMar Pharma Canada Affitech Denmark Pieris Germany Merus Holland Venus Remedies India Opsona Ireland Toppan Japan Otago University New Zealand Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years. United States Advangene IL Loyola Univ. Chicago IL Dow Chemicals MI ScyFIX MN OncBioMune LA Penwest Corp. NY DesignMedix OR PLx TX CreAgri CA New Heaven Pharma CT
  • 13. 13 Aagami Connectivity in India We are connected at CXO Level of TOP 100 Lifesciences companies in India including: Biocon Intas Sun Pharma Cadila Lupin Themis Cipla MicroLabs Torrent Pharma Dr Reddys Piramal USV Glenmark Reliance Wockhardt Hetero Drugs Strides Zydus
  • 14. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com USA (Head Office) Aagami, Inc. 2135 City Gate Lane Suite 300 Naperville, IL 60653 P: +1-630-364-1837 INDIA Aagami 741, Nelson Square Nagpur – 440013 P: +91-712-258-6678 Dinesh Jain Email: dinesh@aagami.com M: +1 630-853-3520 Godwyn Francis Email: godwyn@aagami.com M: +91-787-501-6957 www.aagami.com 14 Realizing Possibilities, Together